High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

Overview of attention for article published in Leukemia, October 2006

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

policy: 1 policy source

patent: 3 patents

Citations

dimensions_citation: 249 Dimensions

Readers on

mendeley: 104 Mendeley

Summary Policy documents Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

Dosage regimes for the administration of an anti-CD19 ADC

Grant US-11938192-B2

United States of America

Dosage regimes for the administration of an anti-CD25 ADC

Grant US-11426467-B2

United States of America

Dosage regimes for the administration of an anti-CD19 ADC

Grant US-11318211-B2

United States of America